Combination transarterial chemoembolization and microwave ablation improves local tumor control for 3- to 5-cm hepatocellular carcinoma when compared with transarterial chemoembolization alone.

Abstract

To compare transarterial chemoembolization (TACE) monotherapy to combination TACE and microwave ablation (MWA) for local control of 3- to 5-cm hepatocellular carcinoma (HCC). Patients with HCC between 3 and 5cm treated with TACE monotherapy or combination TACE+MWA at a single institution between 2007 and 2016 were retrospectively reviewed. Twenty-four HCCs (median diameter 3.8cm) in 16 patients (13 males; median age 64years) were treated using TACE monotherapy. Combination TACE+MWA was used to treat 23 HCCs (median diameter 4.2cm) in 22 patients (18 males; median age 61years). Microwave ablation was performed at a target time of two weeks following TACE. Individual tumors were followed by serial contrast-enhanced CT or MR. Response to treatment was evaluated on a tumor-by-tumor basis using mRECIST criteria with the primary outcome being local tumor progression (LTP). Data were analyzed using Fisher's exact test for categorical variables and Wilcoxon rank sum test for continuous variables. Time to LTP was estimated with the Kaplan-Meier method. Relative to TACE monotherapy, TACE+MWA provided a trend toward both a lower rate of LTP (34.8% vs. 62.5%, p=0.11) and a higher complete response rate (65.2% vs. 37.5%; p=0.12). Time to LTP (22.3months vs. 4.2months; p=0.001) was significantly longer in the TACE+MWA group compared to TACE monotherapy. Combination therapy with TACE and microwave ablation improves local control and increases time to LTP for 3-5cm HCC.